0 10 Activation Activation NNP 11 13 of of IN 14 23 NF-kappaB NF-kappaB NNP 24 26 in in IN 27 40 Mycobacterium Mycobacterium NNP 41 54 tuberculosis- tuberculosis- NN 55 62 induced induce VBD 63 76 interleukin-2 interleukin-2 NN 77 85 receptor receptor NN 86 96 expression expression NN 97 99 in in IN 100 111 mononuclear mononuclear JJ 112 122 phagocytes phagocyte NNS 122 123 . . . 125 132 Soluble soluble JJ 133 146 interleukin-2 interleukin-2 NN 147 161 receptor-alpha receptor-alpha NN 162 163 ( ( ( 163 173 IL-2Ralpha IL-2Ralpha NNP 173 174 ) ) ) 175 178 has have VBZ 179 183 been be VBN 184 192 reported report VBN 193 195 to to TO 196 198 be be VB 199 208 increased increase VBN 209 211 in in IN 212 215 the the DT 216 220 sera serum NNS 221 223 of of IN 224 232 patients patient NNS 233 237 with with IN 238 246 advanced advance VBN 247 259 tuberculosis tuberculosis NN 259 260 , , , 261 264 and and CC 265 271 levels level NNS 272 279 decline decline VBP 280 285 after after IN 286 293 therapy therapy NN 294 296 in in IN 297 307 accordance accordance NN 308 312 with with IN 313 324 improvement improvement NN 325 327 of of IN 328 338 radiologic radiologic JJ 339 347 findings finding NNS 347 348 . . . 349 351 We we PRP 352 364 investigated investigate VBD 365 375 expression expression NN 376 378 of of IN 379 382 the the DT 383 393 IL-2Ralpha IL-2Ralpha NNP 394 396 in in IN 397 412 bronchoalveolar bronchoalveolar JJ 413 419 lavage lavage NN 420 421 ( ( ( 421 424 BAL BAL NNP 424 425 ) ) ) 426 431 cells cell NNS 432 434 in in IN 435 441 active active JJ 442 451 pulmonary pulmonary JJ 452 464 tuberculosis tuberculosis NN 464 465 , , , 466 469 and and CC 470 479 evaluated evaluate VBD 480 483 the the DT 484 493 mechanism mechanism NN 494 507 Mycobacterium Mycobacterium NNP 508 520 tuberculosis tuberculosis NN 521 528 induces induce VBZ 529 531 in in IN 532 535 the the DT 536 546 IL-2Ralpha IL-2Ralpha NNP 547 552 using use VBG 553 556 the the DT 557 562 THP-1 thp-1 NN 563 574 mononuclear mononuclear JJ 575 584 phagocyte phagocyte NN 585 589 cell cell NN 590 594 line line NN 594 595 . . . 596 598 We we PRP 599 604 found find VBD 605 615 IL-2Ralpha IL-2Ralpha NNP 616 626 expression expression NN 627 629 to to TO 630 632 be be VB 633 642 increased increase VBN 643 645 in in IN 646 649 BAL bal NN 650 655 cells cell NNS 656 660 from from IN 661 669 involved involve VBN 670 675 sites site NNS 676 678 of of IN 679 685 active active JJ 686 695 pulmonary pulmonary JJ 696 708 tuberculosis tuberculosis NN 708 709 . . . 710 720 Expression expression NN 721 723 of of IN 724 727 the the DT 728 739 alpha-chain alpha-chain NN 740 742 of of IN 743 753 IL-2Ralpha IL-2Ralpha NNP 754 756 on on IN 757 767 peripheral peripheral JJ 768 773 blood blood NN 774 783 monocytes monocyte NNS 784 785 ( ( ( 785 788 PBM PBM NNP 788 789 ) ) ) 790 793 was be VBD 794 801 induced induce VBN 802 804 by by IN 805 807 M. M. NNP 808 820 tuberculosis tuberculosis NN 821 823 by by IN 824 828 flow flow NN 829 838 cytometry cytometry NN 839 849 evaluation evaluation NN 849 850 . . . 851 859 Northern Northern NNP 860 868 analysis analysis NN 869 881 demonstrated demonstrate VBD 882 891 increased increase VBN 892 902 IL-2Ralpha IL-2Ralpha NNP 903 907 gene gene NN 908 918 expression expression NN 919 924 after after IN 925 936 stimulation stimulation NN 937 941 with with IN 942 944 M. M. NNP 945 957 tuberculosis tuberculosis NN 958 963 which which WDT 964 967 was be VBD 968 975 further further RBR 976 983 induced induce VBN 984 986 by by IN 987 1003 interferon-gamma interferon-gamma NN 1004 1005 ( ( ( 1005 1014 IFN-gamma IFN-gamma NNP 1014 1015 ) ) ) 1015 1016 . . . 1017 1020 The the DT 1021 1031 IL-2Ralpha IL-2Ralpha NNP 1032 1040 promoter promoter NN 1041 1051 containing contain VBG 1052 1055 the the DT 1056 1063 nuclear nuclear JJ 1064 1070 factor factor NN 1071 1076 kappa kappa NN 1077 1078 B B NNP 1079 1080 ( ( ( 1080 1089 NF-kappaB NF-kappaB NNP 1089 1090 ) ) ) 1091 1095 site site NN 1096 1099 was be VBD 1100 1117 transcriptionally transcriptionally RB 1118 1125 induced induce VBN 1126 1128 by by IN 1129 1131 M. M. NNP 1132 1144 tuberculosis tuberculosis NN 1145 1148 and and CC 1149 1153 this this DT 1154 1163 NF-kappaB NF-kappaB NNP 1164 1168 site site NN 1169 1174 could could MD 1175 1181 confer confer VB 1182 1194 inducibility inducibility NN 1195 1197 to to TO 1198 1199 a a DT 1200 1212 heterologous heterologous JJ 1213 1219 herpes herpes NN 1220 1229 thymidine thymidine NN 1230 1236 kinase kinase NNP 1237 1238 ( ( ( 1238 1240 TK TK NNP 1240 1241 ) ) ) 1242 1250 promoter promoter NN 1251 1253 by by IN 1254 1256 M. M. NNP 1257 1269 tuberculosis tuberculosis NN 1269 1270 . . . 1271 1286 Electrophoretic electrophoretic JJ 1287 1295 mobility mobility NN 1296 1301 shift shift NN 1302 1308 assays assay NNS 1309 1310 ( ( ( 1310 1315 EMSAs EMSA NNP 1315 1316 ) ) ) 1317 1325 revealed reveal VBD 1326 1334 specific specific JJ 1335 1342 binding binding NN 1343 1345 of of IN 1346 1353 nuclear nuclear JJ 1354 1361 protein protein NN 1362 1364 to to TO 1365 1368 the the DT 1369 1378 NF-kappaB NF-kappaB NNP 1379 1383 site site NN 1384 1388 upon upon IN 1389 1398 induction induction NN 1399 1403 with with IN 1404 1406 M. M. NNP 1407 1419 tuberculosis tuberculosis NN 1419 1420 . . . 1421 1426 Using use VBG 1427 1437 antibodies antibody NNS 1438 1445 against against IN 1446 1449 the the DT 1450 1453 p50 p50 NN 1454 1457 and and CC 1458 1461 p65 p65 NN 1462 1470 subunits subunit NNS 1471 1473 of of IN 1474 1483 NF-kappaB NF-kappaB NNP 1484 1486 in in IN 1487 1492 EMSAs EMSA NNP 1492 1493 , , , 1494 1497 the the DT 1498 1509 involvement involvement NN 1510 1512 of of IN 1513 1517 both both CC 1518 1521 p50 p50 NN 1522 1525 and and CC 1526 1529 p65 p65 NN 1530 1538 proteins protein NNS 1539 1542 was be VBD 1543 1550 further further RBR 1551 1563 demonstrated demonstrate VBN 1563 1564 . . . 1565 1575 Functional functional JJ 1576 1586 expression expression NN 1587 1589 of of IN 1590 1593 the the DT 1594 1604 IL-2Ralpha IL-2Ralpha NNP 1605 1607 on on IN 1608 1619 mononuclear mononuclear JJ 1620 1630 phagocytes phagocyte NNS 1631 1633 in in IN 1634 1636 M. M. NNP 1637 1649 tuberculosis tuberculosis NN 1650 1659 infection infection NN 1660 1663 may may MD 1664 1668 play play VB 1669 1671 an an DT 1672 1681 important important JJ 1682 1698 immunomodulatory immunomodulatory JJ 1699 1703 role role NN 1704 1706 in in IN 1707 1710 the the DT 1711 1715 host host NN 1716 1724 response response NN 1724 1725 . . .